Supernus Pharmaceuticals is a U.S.-focused specialty CNS biopharmaceutical company whose commercial transition is increasingly visible in reported results. Its growth portfolio comprises Qelbree for ADHD, GOCOVRI for Parkinson’s dyskinesia and off episodes, ZURZUVAE for postpartum depression, and ONAPGO for advanced Parkinson’s motor fluctuations, while Trokendi XR and Oxtellar XR face generic erosion. **Q2 2026 total revenue rose 32.4% to $219.1 million, and growth-product revenue increased 52.0% to $175.7 million.** Qelbree sales were $89.2 million, ZURZUVAE collaboration revenue was $35.4 million, GOCOVRI sales were $37.6 million, and ONAPGO sales reached $13.5 million. Management raised 2026 revenue guidance to $860 million–$890 million and adjusted operating earnings guidance to $150 million–$180 million. GAAP results were distorted by a $54.9 million non-cash APOKYN impairment, producing a $58.4 million net loss, while adjusted operating earnings remained $31.2 million. The stock trades near $41.49 at approximately 2.57x EV/LTM sales, below cited specialty-pharma peer ranges of 3.0x–4.7x, with a $61.75 consensus target. Near-term catalysts are ONAPGO supply resolution and the proposed Indivior merger, which targets $2.2 billion of combined revenue and $125 million of annual synergies.

Supernus Pharmaceuticals Inc (SUPN) Investment Analysis:

1. Executive Summary:

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a specialty biopharmaceutical company focused on the development and commercialization of products for central nervous system (CNS) disorders, including Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Postpartum Depression (PPD), and epilepsy [cite: 1, 2]. The company generates revenue primarily through direct product sales in the United States, supplemented by collaboration revenues derived from strategic commercialization partnerships [cite: 2, 3, 4]. Geographically, Supernus operates predominantly within the U.S. pharmaceutical market, serving a diverse customer base composed of drug wholesalers, specialty pharmacies, and retail pharmacy chains [cite: 3, 4].

Its commercial portfolio is anchored by four primary growth products: Qelbree (extended-release viloxazine), GOCOVRI (extended-release amantadine), ZURZUVAE (zuranolone), and ONAPGO (subcutaneous apomorphine infusion pump) [cite: 3, 4, 5]. The legacy commercial foundation includes extended-release anti-epileptic formulations Trokendi XR and Oxtellar XR, which are currently experiencing generic market erosion [cite: 6, 7].

Product Name	Core Indication	Mechanism / Class	Revenue Model / Q2 2026 Performance
Qelbree	ADHD (Pediatric & Adult)	Non-stimulant, selective norepinephrine reuptake inhibitor	Net Product Sales ($89.2M, +15% YoY) [cite: 3, 4]
GOCOVRI	Parkinson's Disease Dyskinesia & "Off" Episodes	Extended-release NMDA receptor antagonist	Net Product Sales ($37.6M, +2% YoY) [cite: 3, 4]
ZURZUVAE	Postpartum Depression (PPD)	GABA-A receptor positive allosteric modulator	50/50 U.S. Profit Split Collaboration ($35.4M) [cite: 2, 3, 4]
ONAPGO	Advanced Parkinson's Disease Motor Fluctuations	Continuous subcutaneous apomorphine infusion pump	Net Product Sales ($13.5M post-launch) [cite: 3, 4, 5]
Legacy Portfolio	Epilepsy & Migraine Prophylaxis	Extended-release topiramate (Trokendi XR) & oxcarbazepine (Oxtellar XR)	Net Product Sales ($50M–$60M FY2026E) [cite: 3, 4, 6]

The primary customers for Supernus include pharmaceutical wholesalers (such as AmerisourceBergen, Cardinal Health, and McKesson), specialty pharmacies, and retail pharmacy chains, which distribute products to hospitals, clinics, and retail end-users [cite: 4]. Key end markets comprise adult and pediatric neurology, psychiatry, movement disorder specialist clinics, and obstetrics/gynecology practices.

Healthcare providers and patients choose Supernus products over alternative therapies due to differentiated clinical profiles, proprietary extended-release drug delivery technologies (such as Microtrol), non-controlled substance classifications, and reduced dosing frequency [cite: 5, 7, 8]. For instance, Qelbree provides a non-controlled, once-daily non-stimulant treatment alternative in an ADHD market facing chronic Schedule II stimulant shortages [cite: 5, 7]. ONAPGO offers the first continuous subcutaneous apomorphine delivery system in the United States, providing rapid and sustained control over severe motor fluctuations in advanced Parkinson’s disease without requiring invasive surgery [cite: 5].

2. Business Drivers & Strategic Overview:

Product Detail & Core Revenue Drivers

Supernus is executing a corporate transition, replacing its legacy anti-epileptic cash flows with a portfolio of late-stage growth assets in neurology and psychiatry [cite: 6, 7].

• Qelbree (viloxazine extended-release capsules): Approved for pediatric and adult ADHD, Qelbree serves as the primary revenue engine for Supernus [cite: 3, 7]. Total prescriptions grew 17% year-over-year in Q2 2026, supported by a 25% surge in adult prescriptions and a 14% increase in pediatric volume [cite: 3, 4]. Qelbree’s non-stimulant designation avoids Schedule II regulatory hurdles, permitting convenient prescribing, electronic refills, and co-pay support program implementation [cite: 7].
• GOCOVRI (amantadine extended-release): Acquired via Adamas Pharmaceuticals, GOCOVRI is the only FDA-approved medication indicated to treat both "off" time and dyskinesia in Parkinson's disease patients receiving levodopa-based therapy [cite: 6, 9]. It generates stable cash flows with high gross margins, recording $37.6 million in net sales in Q2 2026 [cite: 3, 4].
• ZURZUVAE (zuranolone): Added through the acquisition of Sage Therapeutics in July 2025, ZURZUVAE is co-commercialized in the U.S. under a 50/50 profit-sharing collaboration with Biogen Inc. [cite: 2, 10]. It is a 14-day, once-daily oral treatment that delivers rapid improvements in depressive symptoms for women suffering from postpartum depression [cite: 2]. Collaboration revenues totaled $35.4 million in Q2 2026, reflecting a 53% year-over-year increase in underlying U.S. sales reported by Biogen [cite: 3, 4].
• ONAPGO (apomorphine hydrochloride injection, SPN-830): Launched in April 2025 following FDA approval, ONAPGO is a continuous subcutaneous apomorphine infusion pump designed for advanced Parkinson's disease patients experiencing severe motor fluctuations [cite: 4, 5, 10]. Net sales reached $13.5 million in Q2 2026 [cite: 3, 4]. Since launch through July 2026, over 2,600 patient enrollment forms were submitted by ~720 prescribers [cite: 4]. Management is addressing initial supply constraints by submitting a regulatory filing for a secondary drug supplier in Q3 2026, targeting FDA clearance by mid-2027 [cite: 4, 10].
• Legacy Products (Trokendi XR and Oxtellar XR): Both products have lost exclusivity and face generic erosion [cite: 6, 7]. Trokendi XR net sales declined significantly from historical peaks above $260 million to under $100 million, while Oxtellar XR generic entry began in late 2024 [cite: 6]. Combined full-year 2026 revenues for both legacy drugs are guided at $50 million to $60 million [cite: 3, 4].

Moat Analysis

Supernus maintains an economic moat built on intellectual property, drug delivery formulation technologies, high switching costs, and specialized distribution channels [cite: 4, 5, 8, 11].

• Intellectual Property (IP): Supernus maintains a patent shield across its growth products [cite: 11]. Qelbree is protected by six U.S. Orange Book-listed patents expiring between September 2029 and April 2035 [cite: 11]. GOCOVRI and ONAPGO possess formulation, device, and method-of-use patents extending into the mid-2030s.
• Formulation Technology & High Switching Costs: The company utilizes proprietary extended-release delivery platforms (such as Microtrol) to optimize drug release rates and pharmacokinetic profiles [cite: 8]. In chronic CNS conditions like ADHD and movement disorders, establishing therapeutic stability requires time; once achieved, clinicians and patients face high switching costs due to risks of symptom return or side effects associated with changing medications.
• Specialty Distribution & Infrastructure: Continuous infusion therapies like ONAPGO require dedicated patient onboarding, specialty pharmacy distribution networks, device training, and localized hub support services [cite: 4, 5]. This specialized infrastructure acts as a operational barrier against generic standard-of-care alternatives.

Total Addressable Market (TAM) Analysis

The addressable markets across Supernus' core therapeutic focus areas are substantial and expanding:

• ADHD Market: The U.S. ADHD market generates over 93 million prescriptions annually [cite: 7]. Adult prescriptions represent approximately 67% of total market volume, offering an addressable market for Qelbree [cite: 7]. Ongoing market-wide shortages of stimulant medications continue to push healthcare providers toward established non-stimulant alternatives [cite: 5, 7].
• Parkinson's Disease Fluctuations: Over 1 million individuals in the U.S. live with Parkinson's disease, with approximately 40% developing motor fluctuations and dyskinesia as disease severity progresses [cite: 5]. ONAPGO targets advanced PD patients requiring continuous apomorphine delivery beyond standard oral regimens [cite: 4, 5].
• Postpartum Depression: Postpartum depression affects approximately 1 in 8 new mothers in the U.S., translating to an addressable patient population of ~500,000 women annually [cite: 2]. ZURZUVAE represents the first oral 14-day acute treatment specifically approved for this market [cite: 2].

Competitive Landscape

Supernus competes with major pharmaceutical firms and generic drug manufacturers across its core therapeutic areas:

• ADHD Segment: Competitors include generic atomoxetine (Strattera), extended-release guanfacine (Intuniv), and branded/generic stimulants (Vyvanse, Adderall XR, Concerta). Qelbree is positioned as a once-daily, non-controlled therapy with proven adult and pediatric efficacy, gaining market share within non-stimulant prescribing [cite: 3, 4, 7].
• Parkinson's Disease Segment: Competitors include oral levodopa adjunctive agents (MAO-B inhibitors, COMT inhibitors), acute inhaled apomorphine (Inbrija), and invasive surgical interventions such as Deep Brain Stimulation (DBS). ONAPGO offers continuous, non-surgical apomorphine administration, positioning it between oral adjuncts and invasive surgical procedures [cite: 5].
• PPD Segment: ZURZUVAE holds a unique competitive position as the only oral 14-day acute treatment for PPD, competing primarily against off-label generic SSRIs and Sage/Biogen's intravenous formulation (Zulresso) [cite: 2].

Transformative M&A Landscape: Pending Indivior Merger

On August 3, 2026, Supernus announced a definitive all-stock merger-of-equals agreement with Indivior Pharmaceuticals (NASDAQ: INDV) to create a combined CNS biopharmaceutical platform [cite: 3, 4, 12, 13].

Transaction Feature	Structure / Term Details
Combined Corporate Entity	Supernus, Inc. (retaining ticker SUPN on NASDAQ) [cite: 12, 13, 14]
Executive Leadership	Jack A. Khattar to serve as President and Chief Executive Officer [cite: 12, 13, 14, 15]
Exchange Ratio	Fixed exchange ratio of 1.5401 Indivior common shares per Supernus share [cite: 13, 14]
Ownership Breakdown	Indivior stockholders ~56.5% / Supernus stockholders ~43.5% [cite: 13]
Pre-Closing Special Dividend	Indivior to pay a $1.0 Billion cash dividend to Indivior holders prior to closing [cite: 13, 16]
Pro Forma Financial Scale	~$2.2 Billion in combined pro forma annual revenues [cite: 12, 13, 15]
Synergy Targets	~$125 Million in annual run-rate cost synergies within 12 months [cite: 12, 13, 15]
Anticipated Closing Date	Fourth Quarter of 2026 (subject to stockholder and regulatory approvals) [cite: 13, 15, 16]

This transaction significantly increases commercial scale, pairing Supernus' CNS portfolio with Indivior’s market leadership in addiction treatment (anchored by SUBLOCADE) [cite: 13, 15, 16].

3. Financial Performance & Valuation:

Latest Quarterly Performance: Q2 2026

Supernus announced its second-quarter 2026 financial results on August 3, 2026 [cite: 1, 3, 10].

Financial Metric	Q2 2026 Actual	Q2 2025 Actual	Year-over-Year Growth
Total Revenue	$219.1 Million	$165.5 Million	+32.4% [cite: 1, 3]
Growth Products Revenue	$175.7 Million	$115.6 Million	+52.0% [cite: 3]
Qelbree Net Sales	$89.2 Million	$77.6 Million	+15.0% [cite: 3]
GOCOVRI Net Sales	$37.6 Million	$36.9 Million	+1.9% [cite: 3]
ZURZUVAE Collaboration Rev.	$35.4 Million	$23.1 Million	+53.2% [cite: 3, 4]
ONAPGO Net Sales	$13.5 Million	$0.0 Million (Post-launch)	N/A [cite: 3, 4, 10]
GAAP Operating Income (Loss)	$(58.0) Million	$12.1 Million	N/A (Non-cash impairment) [cite: 1, 3]
GAAP Net Income (Loss)	$(58.4) Million	$22.5 Million	N/A [cite: 1, 3, 4]
GAAP Diluted EPS	$(1.01)	$0.40	N/A [cite: 3, 17]
Non-GAAP Adj. Operating Earnings	$31.2 Million	$40.9 Million	-23.7% [cite: 1, 3]
Cash & Marketable Securities	$372.1 Million	$308.7 Million (Dec 2025)	+20.5% [cite: 3, 4]

Earnings Expectations vs. Actuals

• Revenue Performance: Total revenue of $219.1 million exceeded consensus analyst expectations of $205.6 million by 6.55% [cite: 3, 15, 17].
• Earnings Per Share: GAAP diluted EPS missed consensus estimates (+$0.43 projected vs. -$1.01 reported) [cite: 15, 17]. The GAAP loss was driven by a non-cash $54.9 million intangible asset impairment charge on APOKYN and increased SG&A investments supporting ONAPGO and Qelbree commercialization [cite: 1, 3].

Full-Year Guidance Revisions

Management updated full-year 2026 financial guidance following Q2 performance [cite: 1, 3]:
* Total Revenue: Guidance raised to $860 million–$890 million (up from $840 million–$870 million) [cite: 1, 3].
* Non-GAAP Adjusted Operating Earnings: Guidance raised to $150 million–$180 million (up from $140 million–$170 million) [cite: 1, 3].
* Segment Inclusions: Full-year guidance includes ONAPGO net sales of $55 million–$70 million and combined Trokendi XR / Oxtellar XR net sales of $50 million–$60 million [cite: 3, 4].

Management Commentary & Market Impact

Management noted that growth products now account for over 80% of total company revenues, indicating that the commercial pivot away from legacy Trokendi XR is substantially complete [cite: 3, 6, 7]. Following the simultaneous release of Q2 results, guidance increases, and the Indivior merger agreement, Supernus common stock surged 15.9% in pre-market trading to $51.75 before trading into a merger-arbitrage corridor between $41.00 and $45.00 [cite: 15, 18].

Valuation Multiples & Business Model Connections

Metric / Valuation Parameter	Current Value	Peer / Sector Average
Current Share Price	~$41.49 [cite: 15]	N/A
Market Capitalization	~$2.41 Billion [cite: 1, 10, 15]	Mid-Cap Specialty Pharma
Enterprise Value (EV)	~$2.13 Billion [cite: 19]	N/A
LTM Sales	$830.4 Million [cite: 15, 19]	N/A
EV / LTM Sales	~2.57x [cite: 15, 19]	~3.0x–4.7x [cite: 15]
Price / LTM Sales (P/S)	~2.90x [cite: 15]	~3.0x–4.7x [cite: 15]
Price / Book (P/B)	~2.34x [cite: 15]	~2.60x [cite: 15]
Consensus Price Target	$61.75 (~48.8% upside) [cite: 15]	N/A

Over the past five years, sales grew at a modest ~2.5% CAGR as generic erosion from Trokendi XR offset underlying commercial portfolio growth [cite: 6, 19]. However, with growth products expanding at 52% YoY, top-line growth is re-accelerating [cite: 3]. The market continues to price Supernus at a discount to specialty pharma peers on an EV/Sales basis, reflecting historical revenue drag from mature product losses of exclusivity and near-term merger closing uncertainties [cite: 1, 6, 13, 15].

4. Risk Assessment & Macroeconomic Considerations:

Company-Specific Execution Risks

• ONAPGO Manufacturing & Supply Constraints: Commercial demand for ONAPGO has exceeded initial production capacity [cite: 10]. Supernus is dependent on obtaining FDA approval for a secondary drug supplier in 2027 to avoid product stockouts and support prescription expansion [cite: 4, 10].
• Post-Merger Integration: Combining operations with Indivior involves integrating commercial sales forces, aligning operational systems, and managing corporate realignments [cite: 1, 13, 15]. Failure to achieve the targeted $125 million in annual cost synergies could impact pro forma earnings projections [cite: 12, 13, 15].

Competitive & Pricing Risks

• Gross-to-Net (GTN) Deductions: Commercial formulary access for Qelbree and GOCOVRI requires significant rebates and co-pay assistance programs [cite: 6]. Qelbree’s GTN deductions run in the 50% to 55% range [cite: 6]. Any widening of GTN adjustments could reduce net revenue realization per prescription [cite: 6].

Regulatory & Legal Risks

• Contingent Liabilities & Patent Challenges: Supernus assumed Contingent Value Rights (CVR) obligations under the Sage acquisition (paying $33.4 million for Milestone 1 in May 2026, with potential total payouts up to $234 million) [cite: 1, 10]. Additionally, generic manufacturers routinely seek to challenge Orange Book patents protecting Qelbree and GOCOVRI prior to patent expiration [cite: 11].
• Merger Regulatory Approvals & Financing: Indivior is securing a $650 million debt facility to fund a $1.0 billion pre-closing special dividend [cite: 1, 13]. Tightening credit markets or prolonged antitrust (FTC) reviews could delay transaction closing [cite: 1, 13].

Macroeconomic Sensitivities

• PBM Consolidation & Legislative Reforms: Consolidation among pharmacy benefit managers (PBMs) increases pricing pressure across specialty drug channels, while potential legislative changes to U.S. healthcare policy could impact commercial drug pricing models.

Structured Risk Framework

• What Could Go Wrong:
  • FTC regulatory block or shareholder rejection of the proposed Indivior merger [cite: 1, 13].
  • Unexpected FDA rejection or delay regarding the ONAPGO secondary supplier regulatory submission [cite: 4, 10].
  • Expansion of Qelbree GTN deductions past 60%, impairing net revenue conversion [cite: 6].
• Early Warning Signs:
  • Stagnation in weekly IQVIA prescription volume growth for Qelbree or GOCOVRI [cite: 4].
  • Second-round requests or extended reviews from the FTC regarding the merger S-4 filing [cite: 1, 13].
  • Quarterly GTN realization dropping below 45% in SEC filings [cite: 6].
• Thesis-Breaking Events:
  • Invalidation of core Orange Book patents covering Qelbree prior to 2033 [cite: 11].
  • Persistent supply failures for ONAPGO extending beyond mid-2027 [cite: 4, 10].
  • Post-merger integration challenges leading to revenue dis-synergies across core franchises [cite: 1, 13].

5. 5-Year Scenario Analysis:

The 5-year scenario model projects Supernus' financial trajectory through Fiscal Year 2031 (Year 5). The model utilizes the reference share price of $41.49 [cite: 15] and 58.16 million diluted shares outstanding [cite: 19].

Operating & Financial Assumptions

• Base Case (50% Probability): Growth products expand at a ~9.5% 5-year CAGR, driven by adult Qelbree market share gains and ONAPGO supply resolution by mid-2027 [cite: 4, 7, 10]. Legacy product revenue decays to $15 million annually. Non-GAAP net profit margins stabilize at 26.0% as commercial leverage offsets GTN pressure. Diluted share count expands slightly to 60.0 million. Exit multiple is assumed at 13.0x Non-GAAP P/E.
• High Case (30% Probability): Assumes full merger completion with Indivior, achieving $125 million in run-rate cost synergies and cross-selling scale [cite: 12, 13, 15]. Revenue grows at a 13.5% CAGR, and non-GAAP net margin expands to 30.0%. Share count increases to 61.0 million. Exit multiple expands to 15.0x Non-GAAP P/E, reflecting a broader CNS platform.
• Low Case (20% Probability): Standalone thesis encounters headwinds: ONAPGO supply clearance is delayed, Qelbree GTN deteriorates to 60%, and the Indivior merger fails to close [cite: 1, 6, 10, 13]. Revenue grows at a minor 1.6% CAGR, and non-GAAP net margin contracts to 18.0%. Exit multiple contracts to 9.0x P/E.

5-Year Share Price Trajectory (USD)

Scenario	Current	Year 1 (2027)	Year 2 (2028)	Year 3 (2029)	Year 4 (2030)	Year 5 (2031)
High Case	$41.49	$52.00	$65.50	$81.00	$99.50	$121.65
Base Case	$41.49	$46.50	$52.80	$59.70	$67.30	$76.05
Low Case	$41.49	$37.00	$33.50	$30.20	$28.00	$26.10

Master 5-Year Scenario Summary Table

Scenario	Revenue / Key Scale Metric in Year 5	Margin / Earnings Assumption	Valuation Multiple Assumption	Current Share Price	Implied Future Share Price	5-Year Total Return	Annualized Return	Probability
High Case	$1,650.0 Million	30.0% Net Margin / $8.11 EPS	15.0x Exit P/E	$41.49	$121.65	+193.2%	24.01%	30%
Base Case	$1,350.0 Million	26.0% Net Margin / $5.85 EPS	13.0x Exit P/E	$41.49	$76.05	+83.3%	12.88%	50%
Low Case	$950.0 Million	18.0% Net Margin / $2.90 EPS	9.0x Exit P/E	$41.49	$26.10	-37.1%	-8.84%	20%
Weighted	$1,360.0 Million	25.6% Net Margin / $5.88 EPS	12.8x Exit P/E	$41.49	$79.74	+92.2%	13.96%	100%

ASYMMETRIC UPSIDE POTENTIAL

6. Qualitative Scorecard:

Scorecard Dimension	Score (1–10)	Evaluation Context & Underlying Drivers
Management Alignment	8/10	CEO Jack Khattar holds over 1.2M shares; executive compensation is structured around operational metrics and performance-vesting equity awards [cite: 1, 20, 21, 22].
Revenue Quality	7/10	Branded specialty CNS medications generate gross margins above 85%, offset by GTN rebate obligations and drug wholesaler concentration [cite: 4, 6].
Market Position	8/10	Strong commercial footprint in ADHD and movement disorders; Qelbree leads non-stimulant prescribing growth [cite: 1, 3, 4, 7, 19].
Growth Outlook	8/10	Growth product portfolio expanded revenues 52% YoY in Q2 2026, compensating for legacy Trokendi XR decline [cite: 3, 4, 6, 7].
Financial Health	9/10	Conservative balance sheet with zero funded debt and $372.1 million in cash, cash equivalents, and marketable securities [cite: 3, 4, 11].
Business Viability	8/10	Core products protected by Orange Book patents extending through 2033–2035 and proprietary formulation IP [cite: 7, 8, 11].
Capital Allocation	8/10	Value-accretive corporate development track record, including the Adamas and Sage transactions and the pending Indivior merger [cite: 6, 10, 12, 13].
Analyst Sentiment	8/10	Positive sell-side consensus, with an average 12-month price target of $61.75 (~48.8% potential upside) [cite: 15].
Profitability	7/10	Consistent Non-GAAP operating profitability ($31.2 million in Q2 2026), though GAAP earnings experience non-cash asset impairments [cite: 1, 3].
Track Record	8/10	Proven corporate execution in navigating patent expirations and rebuilding commercial product pipelines [cite: 6, 7].
Overall Score	7.9 / 10	Weighted qualitative operational score reflecting portfolio re-acceleration.

STRONG QUALITATIVE PROFILE

7. Conclusion & Investment Thesis:

Supernus Pharmaceuticals has completed a portfolio transition, replacing its legacy anti-epileptic cash flows with a commercial portfolio focused on central nervous system disorders [cite: 6, 7].

Key Investment Catalysts

• Commercial Growth Portfolio: Combined revenues from Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO grew 52% year-over-year in Q2 2026, prompting management to raise full-year 2026 revenue guidance to $860 million–$890 million [cite: 1, 3, 4].
• ONAPGO Manufacturing Resolution: Submitting an FDA filing for a secondary drug supplier in Q3 2026 is designed to resolve supply constraints and support market penetration in advanced Parkinson's disease by mid-2027 [cite: 4, 5, 10].
• Transformative Scale via Indivior Merger: The proposed all-stock merger with Indivior creates a $2.2 billion revenue CNS biopharmaceutical platform targeting $125 million in annual cost synergies [cite: 12, 13, 15].
• Valuation Cushion: Trading at ~2.57x EV/LTM Sales and ~9.5x Forward Non-GAAP EPS, the stock trades at a valuation discount relative to peer transaction multiples and sell-side price targets ($61.75) [cite: 15, 19].

TRANSFORMATIVE GROWTH PLATFORM

8. Technical Analysis, Price Action & Short-Term Outlook:

Supernus common stock trades near $41.49, hovering near the lower end of its 52-week range ($40.83–$59.68) and consolidating below its 200-day moving average [cite: 15]. Following the Q2 2026 earnings release and simultaneous Indivior merger announcement, the stock jumped pre-market to $51.75 before entering a merger-arbitrage corridor [cite: 15, 18]. In the short term, price action is expected to remain range-bound, tied to the fixed 1.5401 exchange ratio and transaction progress toward closing in Q4 2026 [cite: 13, 14, 16].

CONSOLIDATING AHEAD CATALYSTS

---

1. Supernus Pharmaceuticals, Inc. 8-K Filings - SUPN - Stock Titan, https://www.stocktitan.net/sec-filings/SUPN/8-k.html
2. 2025 Annual Report - Investor Relations | Biogen, https://investors.biogen.com/static-files/05644731-d13f-4279-8f89-304fa1e48827
3. Supernus Announces Second Quarter 2026 Financial Results - Stock Titan, https://www.stocktitan.net/news/SUPN/supernus-announces-second-quarter-2026-financial-wkoh8xqzfgab.html
4. Supernus Pharmaceuticals Reports 32% Second-Quarter 2026 Revenue Growth, Raises Full-Year Guidance and Announces Merger with Indivior | Quiver Quantitative, https://www.quiverquant.com/news/Supernus+Pharmaceuticals+Reports+32%25+Second-Quarter+2026+Revenue+Growth%2C+Raises+Full-Year+Guidance+and+Announces+Merger+with+Indivior
5. Pillr Clinical Insights | Timely Updates for Pharmacy Professionals, https://www.pillrhealth.com/clinical-insights
6. Earnings call: Supernus Pharmaceuticals reports growth despite challenges, https://ng.investing.com/news/stock-market-news/earnings-call-supernus-pharmaceuticals-reports-growth-despite-challenges-93CH-1246129
7. Dear Supernus Stockholder, We are very pleased with our performance in 2023 as we continued to successfully transition from our, https://ir.supernus.com/static-files/4e9d1452-56a0-463b-94ee-70a4e035297b
8. 2025 ANNUAL REPORT - Supernus Pharmaceuticals, https://ir.supernus.com/static-files/694e80b5-09f9-4a0a-9b5e-ddf4eba30031
9. supn-20241231 - SEC.gov, https://www.sec.gov/Archives/edgar/data/1356576/000135657625000017/supn-20241231.htm
10. Supernus Pharmaceuticals, Inc. 10-Q Filings - SUPN - Stock Titan, https://www.stocktitan.net/sec-filings/SUPN/10-q.html
11. Supernus Pharmaceuticals (0LB2) Balance Sheet & Financial Health Metrics, https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-0lb2/supernus-pharmaceuticals-shares/health
12. News - Lawrence, Evans & Co. LLC, http://www.lawrenceevans.com/news/
13. Supernus Pharmaceuticals (NASDAQ: SUPN) plans all-stock merger with Indivior, https://www.stocktitan.net/sec-filings/SUPN/8-k-supernus-pharmaceuticals-inc-reports-material-event-5240b3f9f52b.html
14. Indivior Pharmaceuticals, Inc. (INDV) Leadership & Management Team Analysis, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/management
15. Supernus Stock Price Today | NASDAQ: SUPN Live - Investing.com, https://www.investing.com/equities/supernus-pharmaceuticals-inc
16. Indivior declares $8.13 special dividend contingent on merger - Investing.com UK, https://uk.investing.com/news/stock-market-news/indivior-declares-813-special-dividend-contingent-on-merger-93CH-4872910
17. Supernus Pharmaceuticals (NasdaqGM:SUPN) - Ergebnis- und Umsatzentwicklung, https://simplywall.st/de/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/past
18. Katogen Radar — every biotech catalyst, and who already owns it, https://www.katogen.com/radar
19. SUPN - Supernus Pharmaceuticals Inc Stock Price and Quote - Finviz, https://finviz.com/stock?t=SUPN
20. Supernus Pharmaceuticals, Inc. Form 4 Filings - SUPN - Stock Titan, https://www.stocktitan.net/sec-filings/SUPN/form-4.html
21. SUPERNUS PHARMACEUTICALS, INC., https://ir.supernus.com/static-files/1d1877a3-197b-4293-b408-aa99a5488caa
22. Form DEF 14A for Supernus Pharmaceuticals INC filed 04/30/2026, https://ir.supernus.com/static-files/68440f76-da42-4fec-9d08-fb08aebc7438